Alkyl linked quinolinyl modulators of RORγt

US10555941B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Kristi A. Leonard · West Chester, US
• Kent Barbay · Sunnybrook, US
• James P. Edwards · San Diego, US
• Kevin D. Kreutter · Plainsboro, US
• David A. Kummer · San Diego, US
• Umar Maharoof · North Wales, US
• Rachel Nishimura · San Diego, US
• Maud Urbanski · Flemington, US
• Hariharan Venkatesan · San Diego, US
• Aihua Wang · Jamison, US
• Ronald L. Wolin · San Diego, US
• Craig R. Woods · San Diego, US
• Anne Fourie · San Diego, US
• Xiaohua Xue · San Diego, US
• Maxwell D. Cummings · Strafford, US

Key dates

• Filing date: Mar 14, 2016
• Grant date: Feb 11, 2020
• Expiry date: Mar 14, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/4709
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.